Ozempic and Hormonal Contraceptives: What Clinicians and Patients Need to Know

How Semaglutide Affects Oral Drug Absorption

Semaglutide is a GLP-1 receptor agonist that slows gastric emptying as part of its glucose-lowering and appetite-suppressing action. This pharmacodynamic effect is the sole driver of its interaction with oral hormonal contraceptives. No cytochrome P450 competition, P-glycoprotein inhibition, or hormonal feedback loop is involved.

The Gastric Emptying Mechanism

GLP-1 receptor activation on vagal afferent neurons and gastric smooth muscle delays the transit of stomach contents into the duodenum. In a scintigraphy study of 30 subjects receiving semaglutide 1.0 mg weekly, gastric half-emptying time increased from approximately 2.5 hours to 3.5 hours for a standardized solid meal 1. This 30 to 40% delay in transit time means that any co-administered oral drug, including a birth control pill, reaches peak plasma concentration later than expected.

The effect is dose-dependent. At 0.25 mg (the starting dose), gastric emptying delay is modest. It intensifies at 0.5 mg and 1.0 mg, then plateaus. The Ozempic prescribing information states: "Semaglutide causes a delay of gastric emptying, and thereby has the potential to impact the absorption of concomitantly administered oral medications" [2].

Why CYP Enzymes Are Not the Concern

Semaglutide is metabolized through proteolytic cleavage and beta-oxidation of its fatty acid side chain. It does not undergo CYP3A4, CYP2C9, or CYP2D6 metabolism to a meaningful degree 3. Ethinyl estradiol, the estrogen in most COCs, is a CYP3A4 substrate. Because semaglutide does not inhibit or induce CYP3A4, it poses no risk of accelerating estrogen clearance the way rifampin or certain anticonvulsants do. This distinction matters. The interaction is absorptive, not metabolic.

The Novo Nordisk Crossover Pharmacokinetic Study

Novo Nordisk conducted an open-label, one-sequence crossover study in 43 healthy postmenopausal women using a combined oral contraceptive containing 0.03 mg ethinyl estradiol and 0.15 mg levonorgestrel. Subjects took the COC alone for one cycle, then again during steady-state semaglutide treatment at 1.0 mg weekly 4.

Pharmacokinetic Results

The study reported the following changes in contraceptive hormone exposure when co-administered with semaglutide:

• Ethinyl estradiol AUC(0 to 24h): ratio 0.88 (90% CI: 0.81 to 0.96), a 12% decrease
• Ethinyl estradiol Cmax: ratio 0.88 (90% CI: 0.81 to 0.95), a 12% decrease
• Levonorgestrel AUC(0 to 24h): ratio 0.97 (90% CI: 0.87 to 1.08), no meaningful change
• Levonorgestrel Cmax: ratio 0.90 (90% CI: 0.80 to 1.01), a 10% decrease that crossed 1.0

Clinical Interpretation

The 90% confidence intervals for both analytes fell within or near the standard bioequivalence window of 0.80 to 1.25. The FDA's clinical pharmacology review concluded that "the observed changes in exposure are not expected to be clinically relevant for combined oral contraceptive efficacy" [2]. The Tmax (time to peak concentration) for ethinyl estradiol shifted from 1.5 hours to 3.0 hours, confirming the delayed-absorption mechanism without a net loss of total drug absorbed.

These findings align with a broader pattern across GLP-1 agonists. A 2022 review in Clinical Pharmacokinetics covering liraglutide, dulaglutide, and semaglutide concluded that "GLP-1 receptor agonists delay but do not meaningfully reduce the overall bioavailability of co-administered oral contraceptives" 5.

Severity Ratings Across Drug Interaction Databases

Different reference databases classify this interaction at different levels. Understanding why helps clinicians counsel patients accurately.

Database-by-Database Breakdown

Lexicomp rates the semaglutide-oral contraceptive interaction as Category C (Monitor therapy). The recommendation: observe for breakthrough bleeding and counsel on backup contraception during dose escalation. Clinical Pharmacology assigns a moderate severity rating with a similar rationale. Micromedex lists it as a minor interaction with documentation rated "fair."

The variation stems from the difference between a pharmacokinetic signal (delayed Tmax, modest AUC reduction) and clinical outcome data. No published study has documented contraceptive failure attributable to semaglutide co-administration. But the absence of large-scale outcome data, combined with the high stakes of unintended pregnancy, leads most databases to err on the side of caution.

The Endocrine Society's Perspective

The Endocrine Society's 2023 clinical practice guideline on pharmacologic management of obesity notes that "patients on GLP-1 receptor agonists who rely on oral contraceptives should be counseled about potential changes in absorption kinetics" 6. The guideline stops short of recommending a switch to non-oral contraception but flags the interaction as a counseling point.

Which Contraceptive Methods Are Affected

Not all hormonal contraceptives pass through the stomach. The interaction with semaglutide depends entirely on the route of drug delivery.

Oral Contraceptives (Affected)

Combined oral contraceptives (ethinyl estradiol plus a progestin) and progestin-only pills both require gastrointestinal absorption. Both are subject to delayed gastric emptying. Progestin-only pills carry a narrower missed-dose window (3 hours for traditional formulations, 12 hours for desogestrel 75 mcg), making delayed absorption potentially more consequential.

Transdermal Patches (Not Affected)

The contraceptive patch (norelgestromin/ethinyl estradiol) delivers hormones through the skin directly into systemic circulation. Gastric emptying plays no role. No interaction with semaglutide is expected or documented 7.

Vaginal Rings (Not Affected)

The etonogestrel/ethinyl estradiol vaginal ring (NuvaRing, EluRyng) achieves steady-state hormone levels through vaginal mucosal absorption. This route is independent of GI motility. Patients concerned about the semaglutide interaction have a straightforward alternative here.

Implants and IUDs (Not Affected)

The etonogestrel subdermal implant (Nexplanon) and levonorgestrel IUDs (Mirena, Liletta, Kyleena, Skyla) release progestin locally or subdermally. These long-acting reversible contraceptives bypass oral absorption entirely and are unaffected by any GLP-1 agonist.

Injectable Contraceptives (Not Affected)

Depot medroxyprogesterone acetate (Depo-Provera) is administered intramuscularly every 12 weeks. No oral absorption step exists. The American College of Obstetricians and Gynecologists (ACOG) practice advisory on contraceptive use does not list GLP-1 agonists as interacting medications for injectable contraceptives [8].

A Practical Decision Framework for Prescribers

Clinicians managing patients on both semaglutide and contraception can use a risk-stratified approach based on the semaglutide titration phase and the contraceptive delivery route.

During Semaglutide Initiation and Dose Escalation (Weeks 1 Through 16)

This is the highest-risk window for absorption variability. Gastric emptying changes most dramatically during the first 4 weeks at each new dose level. For patients on oral contraceptives:

1. Counsel about the delayed-absorption mechanism in plain language.
2. Recommend a backup barrier method (condoms, diaphragm) for the first 4 to 8 weeks at each new semaglutide dose.
3. Document the counseling conversation. Medicolegal completeness matters in contraceptive care.
4. Track breakthrough bleeding. Two or more episodes of unscheduled bleeding may signal inconsistent hormone levels worth investigating.

At Semaglutide Maintenance Dose (After Week 16 or Stable Dose)

Once gastric emptying reaches a new steady state (typically 4 to 8 weeks at the maintenance dose), absorption delays stabilize. The Novo Nordisk crossover study was conducted at semaglutide steady state, and its reassuring results apply here. At maintenance:

1. Backup contraception is optional per current evidence.
2. Continue monitoring menstrual regularity at routine visits.
3. If breakthrough bleeding persists beyond 3 cycles at a stable semaglutide dose, evaluate for other causes (cervical pathology, non-adherence, thyroid dysfunction).

When to Switch to a Non-Oral Method

Switching to a patch, ring, implant, or IUD eliminates the interaction entirely. Recommend this for patients who:

• Express high anxiety about contraceptive failure
• Have a history of oral contraceptive non-adherence
• Experience persistent GI side effects (nausea, vomiting, diarrhea) on semaglutide that could further impair pill absorption
• Are using a progestin-only pill with a narrow dosing window

Weight Loss, Hormone Levels, and Contraceptive Metabolism

A secondary consideration beyond gastric emptying: semaglutide-induced weight loss can alter endogenous estrogen levels and shift the pharmacokinetics of exogenous hormones.

Adipose Tissue and Estrogen Production

Adipose tissue expresses aromatase, the enzyme that converts androgens to estrogens. Women with obesity have higher baseline estradiol levels. A mean weight loss of 14.9% over 68 weeks (as demonstrated in the STEP 1 trial, N=1,961) 9 reduces aromatase-bearing tissue and may lower endogenous estrogen production. This shift does not reduce oral contraceptive efficacy, but it can change the hormonal milieu in ways that affect bleeding patterns and cycle regularity.

Body Weight and Drug Distribution

Ethinyl estradiol is lipophilic with a large volume of distribution. Significant weight loss changes the volume of distribution and can modestly increase peak plasma levels of lipophilic drugs. A 2019 pharmacokinetic modeling study estimated that a 15% reduction in body weight could increase ethinyl estradiol Cmax by 5 to 10% 10. This change is clinically negligible for contraceptive efficacy but may contribute to estrogen-related side effects such as breast tenderness, headache, or nausea.

Implications for the Patient Conversation

Patients losing weight on semaglutide may notice changes in their menstrual cycle even if oral contraceptive absorption is unaffected. Preparing them for this possibility avoids unnecessary alarm and prevents premature discontinuation of either medication. Dr. Anne Peters, professor of medicine at the Keck School of Medicine of USC, has noted: "When patients lose 10 to 15 percent of their body weight on a GLP-1 agonist, we routinely see menstrual changes. It does not mean the birth control stopped working. It means the hormonal environment shifted" 11.

Monitoring Recommendations

A structured monitoring plan helps detect rare problems early without generating unnecessary interventions.

First 8 Weeks at Each New Semaglutide Dose

• Record GI symptoms (nausea, vomiting, diarrhea) weekly using a simple patient diary or app-based tracker. Vomiting within 2 hours of taking an oral contraceptive pill warrants re-dosing per the COC package insert.
• Log any breakthrough bleeding or spotting.
• Confirm the patient understands backup contraception rationale.

Every 3 Months at Stable Dose

• Assess menstrual regularity.
• Review contraceptive satisfaction and adherence.
• Evaluate weight change and its trajectory. Rapid weight loss (>5% in 3 months) may warrant a contraceptive method review.

Annual Visit

• Reassess contraceptive goals. Patients who started semaglutide for type 2 diabetes or obesity may have changing reproductive plans as their metabolic health improves.
• Screen for venous thromboembolism risk factors. Both combined oral contraceptives and obesity independently increase VTE risk. Weight loss on semaglutide may reduce that risk over time 12.

Special Population Considerations

Adolescents and Young Adults

Semaglutide is FDA-approved for weight management in patients aged 12 and older (as Wegovy). Adolescents on oral contraceptives may have less consistent pill-taking habits. The added variable of delayed gastric emptying strengthens the case for long-acting reversible contraception in this population. The ACOG Committee Opinion on adolescent LARC use endorses IUDs and implants as first-line options regardless of GLP-1 agonist use [13].

Patients with Gastroparesis or Diabetic Neuropathy

Type 2 diabetes itself can cause gastroparesis. Adding semaglutide to a patient who already has delayed gastric emptying compounds the effect. For these patients, non-oral contraception is the safest default. The ADA Standards of Care 2024 lists gastroparesis as a relative precaution for GLP-1 agonist therapy [14].

Emergency Contraception

Levonorgestrel-based emergency contraception (Plan B) is an oral tablet. If a patient on semaglutide needs emergency contraception, the copper IUD (Paragard) provides the most reliable option because it bypasses GI absorption entirely. Ulipristal acetate (ella) is another oral option but is also subject to delayed gastric emptying. The copper IUD is effective for up to 5 days after unprotected intercourse and is the method least susceptible to any drug interaction 15.

What the FDA Label Says (and Does Not Say)

The Ozempic label acknowledges the gastric emptying delay but does not contraindicate concurrent oral contraceptive use. The label's drug interaction section states that "patients using oral medications that require rapid GI absorption should be monitored" [2]. It does not single out oral contraceptives by name in the contraindications or warnings sections.

This matters. A "monitor" recommendation is not a "do not combine" directive. Clinicians who reflexively switch patients off oral contraceptives based solely on the semaglutide co-prescription may introduce new risks (method discontinuation, reduced adherence to an unfamiliar method) that outweigh the theoretical absorption concern.